User menu

CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.

Bibliographic reference Haufroid, Vincent ; De Meyer, Martine ; Wallemacq, Pierre ; Van Kerckhove, Valérie ; Elens, Laure ; et. al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.. In: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Vol. 6, no. 11, p. 2706-13 (2006)
Permanent URL http://hdl.handle.net/2078.1/10754
  1. Venkataramanan R, Clin Pharmacokinet, 29, 404 (1995)
  2. Hesselink D, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, 10.1016/s0009-9236(03)00168-1
  3. Haufroid Vincent, Mourad Michel, Van Kerckhove Val??rie, Wawrzyniak Jeremie, De Meyer Martine, Eddour Djamila Chaib, Malaise Jacques, Lison Dominique, Squifflet Jean-Paul, Wallemacq Pierre, The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients : , 10.1097/00008571-200403000-00002
  4. Thervet Eric, Anglicheau Dany, King Barry, Schlageter Marie-H??l??ne, Cassinat Bruno, Beaune Philippe, Legendre Christophe, Daly Ann K., Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 : , 10.1097/01.tp.0000090753.99170.89
  5. MacPhee Iain A.M., Fredericks Salim, Mohamed Maha, Moreton Michelle, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians : , 10.1097/01.tp.0000151766.73249.12
  6. Goto Maki, Masuda Satohiro, Kiuchi Tetsuya, Ogura Yasuhiro, Oike Fumitaka, Okuda Masahiro, Tanaka Koichi, Inui Ken-ichi, CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation : , 10.1097/01.fpc.0000114747.08559.49
  7. Zheng HongXia, Zeevi Adriana, Schuetz Erin, Lamba Jatinder, McCurry Kenneth, Griffith Bartley P., Webber Steven, Ristich Julianne, Dauber James, Iacono Aldo, Grgurich Wayne, Zaldonis Diana, McDade Kevin, Zhang Jiong, Burckart Gilbert J., Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism, 10.1177/0091270003262108
  8. Zheng HongXia, Webber Steven, Zeevi Adriana, Schuetz Erin, Zhang Jiong, Bowman Pamela, Boyle Gerard, Law Yuk, Miller Susan, Lamba Jatinder, Burckart Gilbert J., Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms, 10.1034/j.1600-6143.2003.00077.x
  9. van Schaik RH, Clin Chem, 48, 1668 (2002)
  10. Hesselink Dennis A, van Gelder Teun, van Schaik Ron HN, The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?, 10.1517/14622416.6.4.323
  11. MacPhee Iain A. M., Fredericks Salim, Tai Tracy, Syrris Petros, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation, 10.1111/j.1600-6143.2004.00435.x
  12. Hauser I. A., ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation, 10.1681/asn.2004100882
  13. Thummel Kenneth E, A genetic test for immunosuppressant dose selection? : , 10.1097/00008571-200403000-00001
  14. Wallemacq Pierre E., Vanbinst Roger, Asta Stéphanie, Cooper Donald P., High-Throughput Liquid Chromatography-Tandem Mass Spectrometric Analysis of Sirolimus in Whole Blood, 10.1515/cclm.2003.140
  15. Wallemacq PE, Clin Chem, 43, 1989 (1997)
  16. Staatz Christine E, Tett Susan E, Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly : , 10.2165/00002512-200522070-00001
  17. Kuehl Peter, Zhang Jiong, Lin Yvonne, Lamba Jatinder, Assem Mahfoud, Schuetz John, Watkins Paul B., Daly Ann, Wrighton Steven A., Hall Stephen D., Maurel Patrick, Relling Mary, Brimer Cynthia, Yasuda Kazuto, Venkataramanan Raman, Strom Stephen, Thummel Kenneth, Boguski Mark S., Schuetz Erin, 10.1038/86882
  18. Hustert Elisabeth, Haberl Michael, Burk Oliver, Wolbold Renzo, He You-Qun, Klein Kathrin, Nuessler Andreas C., Neuhaus Peter, Klattig Jürgen, Eiselt Regina, Koch Ina, Zibat Arne, Brockmöller Jürgen, Halpert James R., Zanger Ulrich M., Wojnowski Leszek, The genetic determinants of the CYP3A5 polymorphism : , 10.1097/00008571-200112000-00005
  19. Firdaous I, Clin Chem, 41, 1292 (1995)
  20. 20. Immunosuppressive Drugs International Proficiency Testing Scheme URL. http://www.bioanalytics.co.uk
  21. Kamdem L. K., Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus, 10.1373/clinchem.2005.050047
  22. Mai Ingrid, Perloff Elke S., Bauer Steffen, Goldammer Mark, Johne Andreas, Filler Guido, Budde Klemens, Roots Ivar, MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients, 10.1111/j.1365-2125.2004.02182.x
  23. Hoffmeyer S., Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, 10.1073/pnas.050585397